GASTROINTESTINAL STROMAL TÜMÖRLER: DERLEME

Abstract

Gastrointestinal stromal tümörler (GIST) gastrointestinal traktın en sık rastlanan mezenkimal neoplazmlandir. GIST’ler tirozin kinaz reseptörü KIT’in aşırı ekspresyonu ile karakterizedirl-er. GIST sıklıkla mide daha az sıklıkla ekstraduedonal ince barsaklar, kolon ve rektumda görülür. Nadir olarak özefagus ve duedonumda da görülebilir. GIST tedavisinde tek küratif tedavi cerrahidir (lenfadenektomi veya geniş sınırlarla rezeksiyon gerekmeksizin). Tirozin kinaz inhibitörlerinin kullanıma girmesi rezektabl olmayan hastalık için tedavi yaklaşımını değiştirmiştir. Bunlardan biri olan imatinib mesilatın metastatik GIST’lerde sağkalımı uzattığı kanıtlanmıştır. Bu çalışmada GIST ile ilgili literatür değerlendirmesi yapılmıştır.

Keywords

• Gastrointestinal stromal tümör
• mezenkimal neoplazm
• tedavi

GASTROINTESTINAL STROMAL TUMOURS: A LITERATURE REVIEW

Abstract

Gastrointestinal stromal tumors (GIST) are the most common mesenchymal neoplasms of the gastrointestinal tract. GIST are characterized by over-expression of the tyrosine kinase receptor KIT. GIST occur predominantly in the stomach and less frequently in the extraduo-denal small bowel, the colon, and the rectum; rarely, GIST can be found in the esophagus and the duodenum. Surgery is the only curative treatment for GIST(without the need for lymphadenectomy or wide resection margins). The development of tyrosine kinase inhibitors have changed the management of unresectable disease. One of them, imatinib mesylate, has been proved to improve the survival in metastatic GIST. This article reviews literature data on GIST.

Keywords

• Gastrointestinal stromal tumors (GIST)
• mesenchymal neoplasms
• treatment

References

1. 1. Suster S. Gastrointestinal stromatumors. Semin Diag Patho 1996; 13:297-313.
2. 2. Kim CJ, Day S, Yeh KA. Gastrointestinal stromai tumors: Analysis of clinical and pathologicfactors. Am Surg 2001; 67:135-137.
3. 3. Tazawa K, Tsukada K, Makuuchi H, et al. An immunohistochemical and clinicopathological study of gastrointestinal stromal tumors. Pathol 1 nt 1999;49: 786- 798.
4. 4. Lev D, Kariv Y, Issakov J, et at. Gastrointestinal sfromal sarcomas. Br J Surg 1999:86:545-549.
5. 5. Lee JR, Joshi V, Griffin JW, et al. Gastrointestinal autonomic nerve tumor: Immunohistochemical and molecular identity with gastrointestinal stromal tumor. Am J Surg Pathol 2001; 25:979-987.
6. 6. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastroin-testinal pacemaker cell tumour (GIPACT): gastrointestinal stromal tumours show phenotypic characteristics of the interstitial cells of Cajal.Am J Pathol 1998; 152:1259-69.
7. 7. Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP, Emile JF.Gronchi A, Hogendoorn PC, Joensuu H, Le Cesne A, McClure J,Maurel J, Nupponen N,Ray-Coquard I, Reichardt P, Sciot R, Stroobants S, van Glabbeke M, van Oosterom A, Demetri GD; GIST consensus meeting panelists. Consensus meeting for the management of gastro-intestinal stromal tumors. Ann Oncol 2005; 16:566-78.
8. 8. Heinrich M, Corless C, Demetri G, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumour. J Clin Oncol 2003; 21:4342-9.

9. 9. Kalender ME, Sevine A, Tutar E, et al. Effect of sunitinib on metastatic gastrointestinal stromal tumor in patients with neurofibromatosis typel: a case report. World J Gastroenterol 2007; 13:2629-32.
10. 10. Connolly EM, Gaffney E, Reynolds JV. Gastrointestinal stromal tumors. Br J Surg 2003; 90:1178-86.
11. 11. DeMatteo RP, Lewis JJ, Leung 0, et al. Two hundred gastrointestinal stromal tumorsRecurrence patterns and prognostic factors for survival. Ann Surg 2000: 231:51-58.
12. 12. Strickland L, Letson GD, Muro-Cacho CA. Gastrointestinal stromal tumors. Cancer Control 2001: 8:252-261.
13. 13. Sturgeon C, Chejfec G, Espat N. Gastrointestinal stromal tumors: a spectrum of diseases. Surg Oncol 2003; 12:21-6.
14. 14. Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer 2002; 38:39-51.
15. 15. Catena F, Pasqualina E.Campione 0: gatraintestinal stramal tumors ; experience of an emergency urgery department. Dig Surg 2000; 17:503-507.
16. 16. Bucher P, Vİlliger P, Egger JF, et al. Management of gastrointestinal stromal tumours: from diagnosis to treatment. Swiss Med Wkly 2004; 134:145-53.
17. 17. Croom KF, Perry CM. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Drugs 2003; 63:513-22.
18. 18. Silva MV, Reid R. Gastrointestinal stromal tumors (GIST):c-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with imatinib. Pathol Oncol Res 2003; 9:13-9.
19. 19. Muro-Cacho CA, Cantor AB, Morgan M. Prognostic factors in malignant gastrointestinal stromal tumors. Ann Clin Lab Sci 2000; 30:239-247.
20. 20. Wang X, Mori t, Tang W, et at. Gastrointestinal stromal tumors: Ciinicopatho-logical study of Chinese cases. Pathol int 2001; 51:701-706.
21. 21. Angela P. Dei Tas. The reappraisal of gastrointestinal stromal tumors: from Stout ta the KİT revolutian. Virchcws Arch 2003;442:421-428.
22. 22. Pidhorecky I, Cheney RT, Kraybiil V/G, et.al. Gastrointestinal stromal tumors: currentdiagnosis, biologic behavior and management Ann Surg Orcol 2000; 7:705-712.
23. 23. Crosby JA, Catton CN, Davis A, et al. Malignant gastrointestinal stromal tumours of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol 2001; 8:50-9.
24. 24. Neuhaus SJ, Clark MA, Hayes AJ, et al. Surgery for gastrointestinal stromal tumour in the post-imatinib era. ANZ J Surg 2005; 75:165-72.
25. 25. Heikki Joensuu, Fletcher C. Management of gastrointestinal stromal tumors.. Lancet oncology 2002; 3:655-664.
26. 26. Demetri GD, Benjamin RS, Blanke CD.et al. NCCN Task Force Report:Optimal management of patients with gastrointestinal stromal tumor (GIST)-Update of the NCCN Clinical Practice Guidelines. JNCCN 2007; 5:1-29.
27. 27. Nowain A, Bhakta H, Pais S, et al. Gastrointestinal stromal tumors: Clinical profile, pathogenesis, treatment strategies and prognosis. J Gastroenterol Hepatol 2005; 20:818-24.
28. 28. Roberts PJ, Eisenberg B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer 2002; 38:37-8.
29. 29. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumours. Lancet Oncol 2002; 3:655-64.
30. 30. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatin-ib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347:472-80.
31. 31. Karakousis CP, Blumenson LE, Ca-navase G, et.al. Surgery for disseminated abdominal sarcoma . Ann J Surg 1992; 163 :560-564.
32. 32. Peter J. Roberts and Burton Eisenberg. Clinical presentationof gastrointestinal stromal tumors and treatment of operable disease. European Journal of Cancer 2002; 38:37-38.
33. 33. Buchdunger E, O’Reilly T, Wood J. Pharmacology of imatinib (STI571). Eur J Cancer 2002; 38:28-36.
34. 34. Siberman S, Joensuu H. Overview of issues related to imatinib therapy of advanced gastrointestinal stromal tumors: a discussion among the experts. Eur J Cancer 2002; 38:66-9.
35. 35. Demetri G. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). Eur J Cancer 2002; 38:52-9.
36. 36. Van Den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 2002; 38:60-5.
37. 37. Gorre ME, Mohammed M, Ellwood K. et.al. ciinical resistance to ST1571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876- 880.